ReviewLung2026
MUC5B/TGF-β/KL-6 Signaling in Idiopathic Pulmonary Fibrosis: Genetic Susceptibility to Profibrotic Progression and Clinical Perspectives.
Review in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disorder strongly mediated by genetic susceptibility and aberrant epithelial repair mechanisms. Among the identified genetic factors, the MUC5B promoter polymorphism rs35705950 represents the most significant and frequently replicated risk variant associated with both familial and sporadic IPF. This review focuses on the mechanistic role of MUC5B dysregulation in promoting epithelial dysfunction and profibrotic signalling, with particular emphasis on its interaction with transforming growth factor-beta (TGF-β) signalling and KL-6-associated epithelial injury. Excessive MUC5B expression within distal airways disrupts mucociliary homeostasis, prolongs epithelial exposure to inhaled toxic stimuli, and enhances persistent alveolar stress, thereby facilitating chronic epithelial injury and aberrant tissue repair. Sustained epithelial damage subsequently activates TGF-β-mediated SMAD signalling pathways, promoting fibroblast activation, myofibroblast differentiation, and extracellular matrix deposition. Emerging evidence further suggests a close relationship between MUC5B-associated epithelial dysfunction and elevated KL-6 expression, indicating that KL-6 may function as a downstream biomarker indicating ongoing epithelial injury and fibrotic progression. The proposed MUC5B/TGF-β/KL-6 mechanistic signaling provides an integrated molecular network linking genetic susceptibility, epithelial dysfunction, biomarker elevation, and progressive fibrosis in IPF. In addition, telomere-related and surfactant-associated gene mutations further lead to epithelial instability and impaired regenerative capacity. Together, these interconnected molecular mechanisms provide significant insights into IPF progression and may support the development of biomarker-driven prognostic approaches and targeted precision therapies for improved disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.